THE ASSOCIATION BETWEEN THE CYP3A5 GENOTYPE AND TACROLIMUS PHARMACOKINETICS IS WELL ESTABLISHED, AND PATIENTS EXPRESSING FUNCTIONAL CYP3A5 (CARRIERS OF THE CYP3A5*1 ALLELE; EXTENSIVE METABOLIZER), REQUIRE APPROXIMATELY DOUBLE THE STARTING DRUG DOSE. CARRIERS OF CYP3A5*3/*3 OR POOR METABOLIZER REQUIRE HIGHER DOSES.
Why book with us?
Free and On Schedule Sample Collection
24/7 Service
Affordable
Quick and Accurate Reports
3 ML (2 ML MIN.) WHOLE BLOOD IN 1 LAVENDER TOP (EDTA) TUBE. SHIP REFRIGERATED. DO NOT FREEZE.